Laurus Labs had some good news to deliver today morning. The company said that it has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its API Units at  Visakhapatnam, for the inspection conducted in June 2019.

And in FDF segment Laurus Labs received Global Fund (GF) ERP (Expert Review Panel) approval for FDC (Fixed Dose Combination) TLE 400 (Tenofovir/Lamivudine/Efavirenz 300/300/400mg) for supply in GF funded projects.

Laurus Labs is one among the three companies to receive the approval for this product in ART (Anti Retro Viral Therapy).

Following this news, Laurus Labs rose almost 3.5% to Rs.337, with volumes showing a jump of 2 times.